Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm

Bhidayasiri, Roongroj; Jitkritsadakul, Onanong; Friedman, Joseph H.; Fahn, Stanley

doi:10.1016/j.jns.2018.02.010

Cited by 104 publications

(109 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tardive dystonia refers to a dystonia/dyskinesia syndrome associated with exposure to dopamine receptor blocking agents [58]. In contrast to other types of acquired dystonia, tardive dystonia is known to respond well to DBS [59].…”

Section: Tardive Dystoniamentioning

confidence: 99%

Quality of life outcomes after deep brain stimulation in dystonia: A systematic review

Tsuboi

Wong

Okun

et al. 2020

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

Section: Tardive Dystoniamentioning

confidence: 99%

Quality of life outcomes after deep brain stimulation in dystonia: A systematic review

Tsuboi

Wong

Okun

et al. 2020

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

“…It is presumed that any drug exerting direct or indirect anti-D2 properties can be incriminated. Regarding antipsychotics, the emergence of the syndrome seems to be extremely rare following clozapine or quetiapine exposure, probably due to their very low D2 affinity and fast dissociation from the dopamine receptor; in fact, they represent a therapeutic option [26,27]. Numerous case reports are found in the study for several antipsychotic drugs [28][29][30][31].…”

Section: Offending Drugsmentioning

confidence: 99%

“…There are reports of SGAs, including clozapine (as monotherapy or administered with clonazepam), olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, amilsulpiride, and perospirone, being effective as a treatment of TDt [52]. However, switching from FGAs to SGAs as a class has not been consistently proven to benefit [27]. Switching from the offending drug to quetiapine or clozapine seems to make more sense, as both drugs have very low affinity for D2 receptors and are not expected to induce dystonic reactions themselves, but only extremely rarely.…”

Section: Treatmentmentioning

confidence: 99%

Tardive Dystonia due to D2 Antagonists and Other Agents

Σκώκου¹,

Tsermpini²,

Giamarelou³

et al. 2018

Dystonia - Different Prospects

View full text Add to dashboard Cite

Tardive dystonia due to D2 antagonists or other agents is a potentially severe extrapyramidal side effect emerging after long-term drug treatment, prevalent but not limited to psychiatric populations. Its course is often deteriorating, and available treatments are frequently far from satisfying. It presents with sustained muscle contractions, abnormal postures, and repetitive twisting movements and leads to increased psychiatric morbidity, mortality, and decline of quality of life. Inadequate clinical skill and awareness of tardive dystonia can lead to neglect or misdiagnoses, considered as conversion symptoms or of psychogenic origin. Since the syndrome is persistent and often treatment resistant, prevention should be a mainstay of clinical care. Emerging evidence supports positive effects of atypical antipsychotics, particularly quetiapine and clozapine. Therapies such as tetrabenazine, valbenazine, deutetrabenazine, anticholinergics, baclofen, benzodiazepines, vitamin E, or non-pharmacologic interventions, namely botulinum toxin A, deep-brain stimulation, have been found to be helpful in some cases of tardive dystonia. This chapter comprehensively illustrates multiple aspects of this entity, including recent advances on etiology, pathophysiology, clinical presentation, epidemiology, pharmacogenomics, and treatment, aiming to enhance and deepen clinicians' and researchers' awareness of tardive dystonia, with the final goal of ameliorating patients' prognosis and quality of life.

show abstract

“…B. Clozapin oder Quetiapin nicht mehr zu finden. Vielmehr wird die Reduktion auf die niedrigste effektive Dosis des indizierten Antipsychotikums und die Behandlung mit einem der neuen VMAT-2-Inhibitor empfohlen [62]. Insbesondere bei Therapieresistenz und ausgeprägter Alltagseinschränkung ist die Tiefe Hirnstimulation zu diskutieren.…”

Section: Risikofaktoren Und Präventionunclassified

Prävention und Behandlung von Antipsychotika-induzierten tardiven Dyskinesien

Erbe¹

2018

Fortschr Neurol Psychiatr

View full text Add to dashboard Cite

Tardive dyskinesias (TDs) are still common long-term sequelae of antipsychotic treatment. They are generally irreversible and associated with cognitive deficits, a decrease in quality of life and increased mortality. Furthermore, they potentially contribute to further stigmatization of the affected patients. However due to limited treatment options, antipsychotic drugs are still one of the cornerstones in treatment of most severe mental illnesses. Therefore, knowledge about risk factors and prevention of TDs is crucial. If TDs occur, the immediate optimization of the antipsychotic drug regimen is required. Targeted medical treatments such as VMAT - 2 inhibitors can be considered. The novel VMAT-2 inhibitors are not yet approved in Germany. Other drugs that are currently used to treat TDs include clonazepam and gingko biloba. This review summarizes the current evidence of treatment options of TDs and seeks to formulate clinical recommendations for the prevention and management of TDs.

show abstract

Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm

Cited by 104 publications

References 57 publications

Quality of life outcomes after deep brain stimulation in dystonia: A systematic review

Quality of life outcomes after deep brain stimulation in dystonia: A systematic review

Tardive Dystonia due to D2 Antagonists and Other Agents

Prävention und Behandlung von Antipsychotika-induzierten tardiven Dyskinesien

Contact Info

Product

Resources

About